stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) P/B ratio
As of 5 November 2026, Tango Therapeutics, Inc. (TNGX) trades at a P/B ratio of 3.1×. Over the past ten years it has ranged from 0.7× (May 2025) to 9,205× (September 2020); the current reading is higher than 51% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 3.0× | 75.76% |
| FY2024 | 1.7× | (54.64%) |
| FY2023 | 3.7× | 44.91% |
| FY2022 | 2.6× | 30.56% |
| FY2021 | 2.0× | 30.85% |
| FY2020 | 1.5× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Dec 2025 | 3.0× | (48.96%) |
| Sep 2025 | 5.8× | 38.89% |
| Jun 2025 | 4.2× | 362.79% |
| Mar 2025 | 0.9× | (46.43%) |
| 17 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| PBLS Parabilis Medicines, Inc. compare | 0.8× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 2.6× |
| XENE Xenon Pharmaceuticals Inc. compare | 3.0× |
| TNGX Tango Therapeutics, Inc. | 3.1× |
| ABCL AbCellera Biologics Inc. compare | 3.8× |
| RLAY Relay Therapeutics, Inc. compare | 3.9× |
| IOVA Iovance Biotherapeutics, Inc. compare | 4.3× |
| IRON Disc Medicine, Inc. compare | 4.7× |
| EWTX Edgewise Therapeutics, Inc. compare | 9.4× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement